Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Telomir Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of novel therapeutics targeting the biological mechanisms of aging, chronic disease, and cellular dysfunction. The company operates within the biopharmaceutical and life sciences industry, with a specific emphasis on telomere biology and age-related pathologies. Telomir Pharmaceuticals’ core strategy centers on advancing proprietary small-molecule drug candidates designed to protect or restore telomere integrity, which the company believes may have applications across multiple high-unmet-need disease categories.
The company’s primary value driver is its lead drug candidate Telomir-1, which is being investigated for potential use in rare diseases, oncology, and degenerative conditions. Telomir Pharmaceuticals positions itself as a platform-oriented biotech, aiming to leverage a single molecular approach across multiple indications rather than pursuing a single-disease focus. The company was founded in the early 2020s and became publicly traded on the NASDAQ Capital Market under the ticker TELO, evolving from early-stage research into a publicly listed development-stage pharmaceutical company. Some aspects of early corporate history and technology licensing remain data inconclusive based on available public sources.
Business Operations
Telomir Pharmaceuticals operates as a single-reportable-segment biotechnology company, generating no commercial product revenue as of the most recent public filings. Its operations are primarily focused on research and development, including preclinical studies, formulation work, and preparation for regulatory engagement. The company’s business model relies on advancing internally developed drug candidates through early development stages with the potential for future out-licensing, partnerships, or clinical commercialization.
The company does not currently report significant international operations and conducts most activities through its wholly owned operating subsidiary Telomir Pharmaceuticals, Inc. Research activities are conducted through a combination of internal scientific leadership and outsourced contract research organizations. As of the latest available disclosures, Telomir Pharmaceuticals has not announced any material joint ventures, revenue-generating partnerships, or commercial manufacturing assets. Details regarding proprietary manufacturing processes or long-term supply agreements are data inconclusive based on available public sources.
Strategic Position & Investments
Telomir Pharmaceuticals’ strategic direction is centered on advancing Telomir-1 into human clinical trials while expanding its intellectual property portfolio around telomere-focused therapeutics. The company has publicly stated its intent to pursue multiple regulatory pathways, including orphan disease indications, as part of its growth strategy. This approach is designed to reduce development risk and potentially accelerate time to market through smaller, targeted patient populations.
The company has not disclosed any completed material acquisitions of other operating companies. Capital allocation has been directed primarily toward research, patent filings, and public company operating infrastructure following its NASDAQ listing. Telomir Pharmaceuticals has indicated interest in broader applications of telomere science, including inflammatory, metabolic, and oncologic conditions, though specific pipeline expansion plans beyond Telomir-1 remain limited in public disclosures.
Geographic Footprint
Telomir Pharmaceuticals is headquartered in the United States, with its principal executive offices located in New Jersey. The company’s operational footprint is primarily domestic, with research oversight, corporate governance, and regulatory strategy managed from its U.S. headquarters. Laboratory and preclinical work may involve third-party organizations located in other regions, but these arrangements are not disclosed in detail.
The company does not currently report established commercial or research facilities outside the United States, nor does it disclose material foreign subsidiaries. While Telomir Pharmaceuticals has indicated that its therapeutic targets have global market relevance, its international operational presence remains minimal as of the most recent reporting period.
Leadership & Governance
Telomir Pharmaceuticals is led by an executive team with experience in biotechnology, capital markets, and early-stage company development. The leadership team emphasizes a strategy focused on scientific innovation, disciplined capital deployment, and advancing a focused pipeline toward clinical validation. Governance is overseen by a board of directors responsible for strategic oversight, regulatory compliance, and shareholder interests.
Key executives include:
- Erez Aminov – Chief Executive Officer
- Sam Katkovski – Chief Scientific Officer
- Kristin McCarthy – Chief Financial Officer
- Richard A. Wylie – Chairman of the Board
The leadership team has articulated a vision centered on translating telomere science into clinically meaningful therapies, though long-term commercial strategy details remain limited and subject to future regulatory and clinical outcomes.